HGS Refines LymphoStat-B Lupus Trial Design After Phase II Misses Endpoints
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Human Genome Sciences believes it can move ahead with Phase III trials of its systemic lupus erythematosus therapy LymphoStat-B but will refine the clinical study design - including clinical endpoints - from that used in Phase II
You may also be interested in...
HGS/GSK On Track To Initiate Lymphostat-B Phase III Study In 2006
Human Genome Sciences and its development partner GlaxoSmithKline are on track to initiate a Phase III study of LymphoStat-B for the treatment of systemic lupus erythematosus in 2006, HGS said.
Genelabs Prestara update
Genelabs plans to meet with FDA "to discuss the company's options with regard to the development of Prestara [prasterone] for lupus," the firm says June 22. Future development of Prestara also hinges on the outcome of an open-label extension study of a failed confirmatory trial looking at the agent's effect on bone mineral density. The trial is slated to complete in August 2005. "While [the study] may provide useful data on the effect of Prestara on bone mineral density of women with lupus over a longer period of time, the FDA normally does not consider such open-label studies to be sufficient to support approval of a new drug," Genelabs noted. La Jolla is currently conducting a confirmatory trial for its lupus agent Riquent (abetimus) (1Pharmaceutical Approvals Monthly November 2004, p. 13); Immunomedics' monoclonal antibody epratuzumab recently entered Phase III for the autoimmune disease...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011